Goldman Sachs Upgrades Rite-Aid (RAD) to Buy; More Room to Run
Tweet
Share
E-mailGet Alerts RAD Hot Sheet
Price: $0.65 --0%
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Goldman Sachs upgraded Rite-Aid (NYSE: RAD) from Neutral to Buy with a price target of $8.00 (from $5.00) saying they still see room to run in recovery story.
Analyst Robert P. Jones said, "Despite the 80% move in the stock (vs. S&P 11%) since September 2013, we still see upside in the company's turnaround. Two key elements to the story are store remodels and balance sheet deleveraging, and the expanded agreement with MCK should allow for the acceleration of one or both."
He added, "Importantly, on its core outlook, we see stronger comp growth ahead, which should only be compounded by RAD’s higher exposure to states that expanded Medicaid (65% of stores vs. 47% for CVS and 54% for WAG; analysis within). On valuation, RAD screens relatively in-line with its peer average on EV/EBITDA, but we believe the value of its NOLs (PV of $1.6bn on its balance sheet) should be factored in. Treating the NOLs as cash, RAD trades at 8.1x NTM EV/EBITDA, vs. CVS/WAG 9.3x/10.4x."
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $6.44 yesterday.
Analyst Robert P. Jones said, "Despite the 80% move in the stock (vs. S&P 11%) since September 2013, we still see upside in the company's turnaround. Two key elements to the story are store remodels and balance sheet deleveraging, and the expanded agreement with MCK should allow for the acceleration of one or both."
He added, "Importantly, on its core outlook, we see stronger comp growth ahead, which should only be compounded by RAD’s higher exposure to states that expanded Medicaid (65% of stores vs. 47% for CVS and 54% for WAG; analysis within). On valuation, RAD screens relatively in-line with its peer average on EV/EBITDA, but we believe the value of its NOLs (PV of $1.6bn on its balance sheet) should be factored in. Treating the NOLs as cash, RAD trades at 8.1x NTM EV/EBITDA, vs. CVS/WAG 9.3x/10.4x."
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $6.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alpine Income Property Trust (PINE) PT Lowered to $18 at Jones Trading
- Shopify (SHOP) stock rating raised at Morgan Stanley
- Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
